<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253626</url>
  </required_header>
  <id_info>
    <org_study_id>54788</org_study_id>
    <nct_id>NCT04253626</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia</brief_title>
  <official_title>Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the extent to which treatment of iron deficiency anemia beyond 24-34 weeks'&#xD;
      gestation of pregnancy with intravenous iron increases hemoglobin compared to oral iron. The&#xD;
      investigators will test the hypothesis that pregnant women who are anemic in the second and&#xD;
      third trimester are more likely to significantly increase their hemoglobin with intravenous&#xD;
      iron as opposed to the usual standard of care, oral iron.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Hemoglobin value before and after intervention</measure>
    <time_frame>From the date of randomization to four weeks after the intervention</time_frame>
    <description>Hemoglobin is measured as g/dL at enrollment and after the study intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Anemia, Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Intravenous iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 510mg intravenous iron ferumoxytol, with a maximum of 2 doses based on the baseline hemoglobin level. The ferumoxytol is administered as an infusion for approximately 15 - 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin &lt; 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol Injection [Feraheme]</intervention_name>
    <description>510mg intravenous ferumoxytol</description>
    <arm_group_label>Intravenous iron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Sulfate</intervention_name>
    <description>325mg oral ferrous sulfate</description>
    <arm_group_label>Oral iron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women 18 years old and above receiving prenatal care at Stanford/LPCH OB clinic&#xD;
&#xD;
          2. Hemoglobin &lt; 11 g/dL, serum ferritin &lt; 30 ug/dL and or transferrin saturation (TSAT) &lt;&#xD;
             20%&#xD;
&#xD;
          3. Between 24-34 weeks' pregnancy&#xD;
&#xD;
          4. Singleton pregnancy&#xD;
&#xD;
          5. Viable Pregnancy&#xD;
&#xD;
          6. Hemodynamically stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable to give informed consent&#xD;
&#xD;
          2. Known allergy/hypersensitivity to IV iron&#xD;
&#xD;
          3. Inflammatory Bowel Disease or history of gastric bypass surgery&#xD;
&#xD;
          4. Chronic Kidney Disease&#xD;
&#xD;
          5. Known Hemoglobinopathies such as sickle cell disease, beta-thalassemia, alpha&#xD;
             thalassemia&#xD;
&#xD;
          6. Folate/Vitamin B12 deficiency&#xD;
&#xD;
          7. Known malignancy&#xD;
&#xD;
          8. History of multiple medication allergies (&gt; 2 allergies)&#xD;
&#xD;
          9. Hemoglobin above 12 or less than 7 g/dL&#xD;
&#xD;
         10. Patients with complex past medical histories which may include history of multiple&#xD;
             medication allergies, connective tissue disorder, etc.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Lyell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Girsen</last_name>
    <phone>6504604902</phone>
    <email>agirsen@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imee Datoc</last_name>
    <phone>6507255720</phone>
    <email>idatoc@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University School of Medicine/Lucile Packard Childrens Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Girsen, PhD</last_name>
      <phone>650-725-5720</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Deirdre Judith Lyell</investigator_full_name>
    <investigator_title>Professor, Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

